Patents by Inventor Heinz Lubenau

Heinz Lubenau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALMONELLA-BASED VECTORS FOR CANCER IMMUNOTHERAPY TARGETING WILMS' TUMOR GENE WT1
    Publication number: 20180163169
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: January 16, 2018
    Publication date: June 14, 2018
    Inventors: Heinz LUBENAU, Marco SPRINGER
  • NOVEL CMV PP65 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
    Publication number: 20180153976
    Abstract: The present invention relates to an attenuated strain of Salmonella comprising a DNA molecule encoding CMV pp65. In particular, the present invention relates to the use of said attenuated strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 7, 2018
    Inventor: Heinz Lubenau
  • -based vectors for cancer immunotherapy targeting wilms' tumor gene WT1
    Patent number: 9920297
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: March 20, 2018
    Assignee: VAXIMM AG
    Inventors: Heinz Lubenau, Marco Springer
  • NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
    Publication number: 20180064794
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: October 17, 2017
    Publication date: March 8, 2018
    Inventors: Marco SPRINGER, Heinz LUBENAU
  • Method for producing high yield attenuated strains
    Patent number: 9493738
    Abstract: This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 15, 2016
    Assignee: VAXIMM AG
    Inventors: Heinz Lubenau, Holger Siede, Renate Janssen, Marco Springer
  • NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
    Publication number: 20160317634
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Applicant: Vaximm GMBH Mafinex-Technologiezentrum
    Inventors: Marco SPRINGER, Heinz LUBENAU
  • Methods of preparing a liquid formulation of G-CSF
    Patent number: 9468685
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 18, 2016
    Assignee: RATIOPHARM GMBH
    Inventors: Walter Hinderer, Heinz Lubenau
  • DNA VACCINE FOR USE IN PANCREATIC CANCER PATIENTS
    Publication number: 20160250311
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: May 18, 2016
    Publication date: September 1, 2016
    Inventor: Heinz Lubenau
  • DNA vaccine for use in pancreatic cancer patients
    Patent number: 9415098
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: August 16, 2016
    Assignee: VAXIMM AG
    Inventor: Heinz Lubenau
  • SALMONELLA-BASED VECTORS FOR CANCER IMMUNOTHERAPY TARGETING WILMS' TUMOR GENE WT1
    Publication number: 20160068801
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 10, 2016
    Inventors: Heinz LUBENAU, Marco SPRINGER
  • DNA VACCINE FOR USE IN PANCREATIC CANCER PATIENTS
    Publication number: 20150165011
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: June 26, 2013
    Publication date: June 18, 2015
    Inventor: Heinz Lubenau
  • Methods of treatment using glycopegylated G-CSF
    Patent number: 9050304
    Abstract: The present invention provides a glycopegylated G-CSF that is therapeutically active and which has pharmacokinetic parameters and properties that are improved relative to an identical, or closely analogous, G-CSF peptide that is not glycopegylated. Furthermore, the invention provides methods for mobilizing hematopoiesis in a subject, particularly a subject who has received or will receive radiation or chemotherapy treatment. The methods and compositions of the invention can further be used to prevent, alleviate and treat the myelosuppressive effects such therapies.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: June 9, 2015
    Assignee: ratiopharm GmbH
    Inventors: David A. Zopf, Heinz Lubenau
  • LIQUID FORMULATION OF G-CSF
    Publication number: 20150125420
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Application
    Filed: January 9, 2015
    Publication date: May 7, 2015
    Inventors: Walter Hinderer, Heinz Lubenau
  • Method of treatment using stable liquid formulation of G-CSF
    Patent number: 8946161
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 3, 2015
    Assignee: Ratiopharm GmbH
    Inventors: Walter Hinderer, Heinz Lubenau
  • Method for Producing High Yield Attenuated Salmonella Strains
    Publication number: 20140349274
    Abstract: This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 27, 2014
    Applicant: Vaximm AG
    Inventors: Heinz Lubenau, Holger Siede, Renate Janssen, Marco Springer
  • LIQUID FORMULATION OF G-CSF
    Publication number: 20140030214
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Application
    Filed: October 2, 2013
    Publication date: January 30, 2014
    Applicant: BIOGENERIX GMBH
    Inventors: Walter Hinderer, Heinz Lubenau
  • Stable liquid formulations of G-CSF
    Patent number: 8562967
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: October 22, 2013
    Assignee: Biogenerix AG
    Inventors: Walter Hinderer, Heinz Lubenau
  • LIQUID FORMULATIONS OF G-CSF
    Publication number: 20100216698
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Application
    Filed: August 27, 2008
    Publication date: August 26, 2010
    Applicant: BIOGENERIX AG
    Inventors: Walter Hinderer, Heinz Lubenau
  • METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF
    Publication number: 20100120666
    Abstract: The present invention provides a glycopegylated G-CSF that is therapeutically active and which has pharmacokinetic parameters and properties that are improved relative to an identical, or closely analogous, G-CSF peptide that is not glycopegylated. Furthermore, the invention provides methods for mobilizing hematopoiesis in a subject, particularly a subject who has received or will receive radiation or chemotherapy treatment. The methods and compositions of the invention can further be used to prevent, alleviate and treat the myelosuppressive effects such therapies.
    Type: Application
    Filed: April 1, 2008
    Publication date: May 13, 2010
    Applicant: BIOGENERIX AG
    Inventors: David A. Zopf, Heinz Lubenau